Evaluation of Paraoxonase, Arylesterase and Malondialdehyde Levels in Schizophrenia Patients Taking Typical, Atypical and Combined Antipsychotic Treatment
[ X ]
Tarih
2016
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Korean Coll Neuropsychopharmacology
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Objective: Human serum paraoxonase (PON1) prevents lipids from peroxidation and functions as an antioxidant mechanism. Malonyldialdehyde (MDA) is the final product of lipid peroxidation and can be used as an indicator of oxidative stress. The aim of this study was to investigate PON1, MDA, and arylesterase (ARY) levels in schizophrenic patients who, are taking typical, atypical, or combined (typical and atypical) antipsychotic drug treatment, with respect to those of healthy controls, Methods: We evaluated 41 patients (11 taking typical antipsychotics, 19 taking atypical antipsychotics, 11 taking combined anti psychotics) and 43 healthy controls. Results: MDA levels were higher in schizophrenic patients taking typical antipsychotics compared with healthy controls (p=0.001). ARY levels were higher in patients taking atypical antipsychotics compared with healthy controls (p=0.005): PON1 activity was similar in all groups. Conclusion: Our results indicate that treatment with typical antipsychotic drugs could be related to increased MDA levels; and antipsychotic medication may increase PON1 levels in schizophrenic patients.
Açıklama
Anahtar Kelimeler
Paraoxonase, Arylesterase, Malondialdehyde, Schizophrenia, Antipsychotics, Treatment
Kaynak
Clinical Psychopharmacology and Neuroscience
WoS Q Değeri
Q3
Scopus Q Değeri
Q2
Cilt
14
Sayı
4
